Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats

We previously developed a potent candidate vaccine against bovine brucellosis caused by Brucella abortus using the influenza viral vector expressing Brucella Omp16 and L7/L12 proteins (Flu-BA). Our success in the Flu-BA vaccine trial in cattle and results of a pilot study in non-pregnant small ruminants prompted us in the current study to test its efficacy against B. melitensis infection in pregnant sheep and goats. In this study, we improved the Flu-BA vaccine formulation and immunization method to achieve maximum efficacy and safety. The Flu-BA vaccine formulation had two additional proteins Omp19 and SOD, and administered thrice with 20% Montanide Gel01 adjuvant, simultaneously by both subcutaneous and conjunctival routes at 21 days intervals in pregnant sheep and goats. At 42 days post-vaccination (DPV) we detected antigen-specific IgG antibodies predominantly of IgG2a isotype but also IgG1, and also detected a strong lymphocyte recall response with IFN-γ production. Importantly, our candidate vaccine prevented abortion in 66.7% and 77.8% of pregnant sheep and goats, respectively. Furthermore, complete protection (absence of live B. melitensis 16M) was observed in 55.6% and 66.7% of challenged sheep and goats, and 72.7% and 90.0% of their fetuses (lambs/yeanlings), respectively. The severity of B. melitensis 16M infection in vaccinated sheep and goats and their fetuses (index of infection and rates of Brucella colonization in tissues) was significantly lower than in control groups. None of the protection parameters after vaccination with Flu-BA vaccine were statistically inferior to protection seen with the commercial B. melitensis Rev.1 vaccine (protection against abortion and vaccination efficacy, alpha = 0.18–0.34, infection index, P = 0.37–0.77, Brucella colonization, P = 0.16 to P > 0.99). In conclusion, our improved Flu-BA vaccine formulation and delivery method were found safe and effective in protecting pregnant sheep and goats against adverse consequences of B. melitensis infection.

[1]  G. Renukaradhya,et al.  First evaluation of an influenza viral vector based Brucella abortus vaccine in sheep and goats: Assessment of safety, immunogenicity and protective efficacy against Brucella melitensis infection. , 2016, Veterinary microbiology.

[2]  M. Orynbayev,et al.  Simultaneous subcutaneous and conjunctival administration of the influenza viral vector based Brucella abortus vaccine to pregnant heifers provides better protection against B. abortus 544 infection than the commercial B. abortus S19 vaccine. , 2016, Vaccine.

[3]  K. Tabynov.  Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice , 2016, Expert review of vaccines.

[4]  K. Tabynov,et al.  Prime-booster vaccination of cattle with an influenza viral vector Brucella abortus vaccine induces a long-term protective immune response against Brucella abortus infection. , 2016, Vaccine.

[5]  K. Tabynov,et al.  Safety of the novel influenza viral vector Brucella abortus vaccine in pregnant heifers , 2015 .

[6]  K. Tabynov,et al.  An influenza viral vector Brucella abortus vaccine induces good cross-protection against Brucella melitensis infection in pregnant heifers. , 2015, Vaccine.

[7]  S. Ryskeldinova,et al.  Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine. , 2014, Australian veterinary journal.

[8]  K. Tabynov,et al.  Novel vector vaccine against Brucella abortus based on influenza A viruses expressing Brucella L7/L12 or Omp16 proteins: evaluation of protection in pregnant heifers. , 2014, Vaccine.

[9]  K. Tabynov,et al.  Safety of the novel vector vaccine against Brucella abortus based on recombinant influenza viruses expressing Brucella L7/L12 and OMP16 proteins, in cattle , 2014 .

[10]  K. Tabynov,et al.  Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection. , 2014, Vaccine.

[11]  B. Ferko,et al.  Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection , 2014, Virology Journal.

[12]  D. O’Callaghan,et al.  Brucella genomics as we enter the multi-genome era. , 2011, Briefings in functional genomics.

[13]  J. Gaucheron,et al.  Microgel particulate adjuvant: characterisation and mechanisms of action , 2010 .

[14]  J. Gorvel,et al.  Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. , 2009, Vaccine.

[15]  Marcel Tanner,et al.  Human Benefits of Animal Interventions for Zoonosis Control , 2007, Emerging infectious diseases.

[16]  Fabienne Cortade,et al.  Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. , 2007, Vaccine.

[17]  M. Durán-Ferrer,et al.  Antibody response and antigen-specific gamma-interferon profiles of vaccinated and unvaccinated pregnant sheep experimentally infected with Brucella melitensis. , 2004, Veterinary microbiology.

[18]  R. Cox,et al.  Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.

[19]  E. Moreno,et al.  Rough vaccines in animal brucellosis: structural and genetic basis and present status. , 2004, Veterinary research.

[20]  G. Splitter,et al.  Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans , 2003, Clinical Microbiology Reviews.

[21]  Nammalwar Sriranganathan,et al.  Brucellosis vaccines: past, present and future. , 2002, Veterinary microbiology.

[22]  S. Hagius,et al.  Pathogenicity and protective activity in pregnant goats of a Brucella melitensis Deltaomp25 deletion mutant. , 2002, Research in veterinary science.

[23]  A. Benkirane,et al.  Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes. , 2001, Revue scientifique et technique.

[24]  J. Letesson,et al.  Outer Membrane Proteins Omp10, Omp16, and Omp19 of Brucella spp. Are Lipoproteins , 1999, Infection and Immunity.

[25]  B. Garin‐Bastuji,et al.  Brucella melitensis infection in sheep: present and future. , 1998, Veterinary research.

[26]  G. Splitter,et al.  CD8+ Type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I‐ and class II‐deficient mice , 1995, European journal of immunology.

[27]  M. Plommet.  Control y profilaxis. , 1994 .

[28]  G. Splitter,et al.  Sequences of the rplJL operon containing the L10 and L7/L12 genes from Brucella abortus. , 1994, Gene.

[29]  X. Jiang,et al.  Effects of cytokines on intracellular growth of Brucella abortus , 1993, Infection and immunity.

[30]  B. Bricker,et al.  Cloning, expression, and occurrence of the Brucella Cu-Zn superoxide dismutase , 1990, Infection and immunity.